The stock is currently up 0.23 to a new 52-week high of 32.35
Bristol-Myers (BMY) is close to completing a groundbreaking treatment for Hepatitis C that could be launched by 2015 and produce as much as $2.9B in global sales five years later, according to a Citi analyst. Hepatitis C is the primary cause of liver transplants in the U.S. and is expected to become a larger public health issue as baby boomers age.
How's this for a chart:
No comments:
Post a Comment